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out by a Department of Radiology integrating screening 
and diagnostics in the context of a Breast Unit. We recom-
mend the adoption of protocols dedicated to women pre-
viously treated for BC, with a clear definition of respon-
sibilities, methods for invitation, site(s) of visits, methods 
for clinical and radiological evaluation, follow-up duration, 
role and function of family doctors and specialists. These 
Abstract Women who were previously treated for breast 
cancer (BC) are an important particular subgroup of women 
at intermediate BC risk. Their breast follow-up should be 
planned taking in consideration a 1.0–1.5 % annual rate of 
loco-regional recurrences and new ipsilateral or contralat-
eral BCs during 15–20 years, and be based on a regional/
district invitation system. This activity should be carried 
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women will be invited to get a mammogram in dedicated 
sessions starting from the year after the end of treatment. 
The planned follow-up duration will be at least 10 years 
and will be defined on the basis of patient’s age and pref-
erences, taking into consideration organizational matters. 
Special agreements can be defined in the case of women 
who have their follow-up planned at other qualified centers. 
Dedicated screening sessions should include: evaluation of 
familial/personal history (if previously not done) for identi-
fying high-risk conditions which could indicate a different 
screening strategy; immediate evaluation of mammograms 
by one or, when possible, two breast radiologists with 
possible addition of supplemental mammographic views, 
digital breast tomosynthesis, clinical breast examination, 
breast ultrasound; and prompt planning of possible further 
workup. Results of these screening sessions should be set 
apart from those of general female population screening 
and presented in dedicated reports. The following research 
issues are suggested: further risk stratification and effec-
tiveness of follow-up protocols differentiated also for BC 
pathologic subtype and molecular classification, and evalu-
ation of different models of survivorship care, also in terms 
of cost-effectiveness.
Keywords Breast cancer · Follow-up · Mammography · 
Screening · Survivorship care
Introduction
This position paper on recommendations for breast imag-
ing follow-up of women with a previous history of breast 
cancer (BC) is the result of an agreement between the 
Italian Group for Mammography Screening (GISMa) and 
the Italian College of Breast Radiologists (ICBR) by the 
Italian Society of Medical Radiology (SIRM). The decision 
to provide this paper was taken at the end of a joint GISMa/
ICBR-SIRM workshop held in Reggio Emilia on May 8, 
2015 in the context of GISMa annual meeting. The text has 
been approved by the GISMa Coordination Board and the 
ICBR-SIRM Board of Directors.
Background
In Italy, according to the Italian Association of Cancer Reg-
istries (AIRTUM) [1], female BC survivors in 2015 were 
about 693,000, equal to 2.2 % of female population and to 
42 % of overall cancer prevalence among women.
After conservative treatment, a peak of ipsilateral true 
loco-regional recurrences is observed during the first 
5 years, in particular the first 2 years; thereafter, this risk 
is progressively fading [2]. This temporal trend is similar 
to that of distant metastases [3]. Conversely, the risk of a 
new primary contralateral BC and its cumulative inci-
dence increase over time: the majority of these events are 
observed after the first 5 follow-up years [4, 5]. This risk 
profile can be applied also to women who underwent uni-
lateral mastectomy. Among ipsilateral recurrences too, the 
new primary BCs (about 50 % of recurrences) have a later 
onset [6]. Thus, the overall incidence of true loco-regional 
recurrences and of new primary BCs shows a steady annual 
rate of 1.0–1.5 % during 15–20 years [7], resulting in a 
continuous increase of the cumulative incidence [4, 8].
Studies reporting higher relapse rates during the first 
3 years [3] or 3–5 years [2, 9] included true loco-regional 
recurrences, new primary ipsilateral BCs, and distant 
metastases but excluded the new primary contralateral BCs. 
As a consequence, the authors observed an early peak of 
events, which biased guidelines and recommendations 
issued by medical societies and governmental agencies.
Breast imaging follow-up should be planned accounting 
for an overall annual rate of loco-regional recurrences and 
new primary ipsilateral or contralateral BCs equal to 1.0–
1.5 % during 15–20 years. A more intensive breast surveil-
lance during the first 3–5 years and a subsequent less inten-
sive surveillance have no rational bases [8, 10]. Women 
with a previous BC history should be considered as an 
important particular subset of women with an intermediate 
BC risk, lower than that of BRCA or p53 mutation carriers 
and higher than that of women with neither personal nor 
familial BC history, or with only sporadic BCs among their 
relatives [11].
No evidence is available from randomized controlled tri-
als on effectiveness of breast imaging follow-up in terms 
of mortality reduction. Observational studies comparing 
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women undergoing different follow-up strategies includ-
ing annual or biannual mammography versus no follow-up 
reported variable mortality reductions or an increased long-
term survival independent of lead time [12–15]. No studies 
reported a comparison in terms of effectiveness between 
clinical/radiological follow-up in a diagnostic context versus 
invitation to a population-based organized screening pro-
gram [16]; moreover, no studies reported on the effectiveness 
of annual versus biannual follow-up mammography [15].
The value of clinical breast examination (CBE) for 
women with a previous personal BC history is uncertain. 
Technical development of mammography (in particular 
from film-screen to digital [17]) and quality assurance pro-
grams reduced the rate of relapses diagnosed with CBE to 
only 15 % [10]. Notably, the relapses diagnosed with CBE 
are associated with a shorter survival than those diagnosed 
with mammography [10]. However, CBE still has a role 
in diagnosing axillary recurrences as well as metastases at 
supraclavicular region or thoracic wall and for the examina-
tion of the surgical scar. Moreover, CBE is a relevant occa-
sion for getting information about the patient’s personal 
and family history in the context of a cancer survivorship 
care, paying also attention to psychological issues.
No studies demonstrated a survival benefit from an ear-
lier diagnosis of asymptomatic breast recurrence/relapse 
using magnetic resonance imaging (MRI) [11, 18] or breast 
ultrasound [11].
International guidelines differ in many important issues 
of breast follow-up of women with a previous BC history: 
frequency of clinical mammography and possible CBE; 
(re)inclusion in population-based organized screening pro-
grams and timing for this inclusion; frequency of screen-
ing mammography also considering the individual risk pro-
file [19–23]. As mentioned above, some medical societies 
and governmental bodies recommend a higher frequency 
of mammography and CBE during the first 3–5 years [19, 
22, 23], even though the temporal trend of the true loco-
regional recurrences and new primary ipsilateral and con-
tralateral tumors does not support this recommendation.
For population-based organized screening programs, 
the management of women previously treated for BC is an 
open issue. These women are excluded from screening pro-
grams in many countries [24–26] but are included in other 
countries [27–29]. Different policies are adopted at the 
regional level in some countries such as in Canada, where 
some regional programs invite women previously treated 
for BC to screening mammography even though the data 
are excluded from standard statistical analysis of the pro-
grams’ performance [30].
In Italy, the GISMa has so far recommended to exclude 
from invitation only those women who are certainly fol-
lowed up at clinical centers. In fact, many regional pro-
grams exclude from invitation all women previously treated 
for BC in a systematic manner. This practice is a matter for 
debate [31, 32] because only half of health care districts are 
served by an active follow-up service and only half of pro-
grams (re)invite these women after a variable time since the 
BC event (2015 GISMa survey, unpublished data).
Follow-up protocols also vary greatly in the diagnos-
tic/clinical context, given the lack of reliable effectiveness 
studies [33]. The screening practice too, whether organ-
ized or spontaneous, contributes to this variability: screen-
detected cancers amplify the heterogeneity of biological 
profiles of BCs as a length bias effect [34]. Of note, the use 
of different follow-up protocols according to the individual 
biological tumor profile is practice commonly performed 
but not validated. Only one model for risk estimation of 
annual loco-regional recurrence has been developed [35].
The definition of breast imaging follow-up protocols for 
women previously treated for BC is necessarily influenced 
by the debate on organizational issues for BC care and, in a 
more general perspective, on follow-up in cancer patients. 
On the one side, the Breast Unit model is increasingly 
applied as a territorial facility for multidisciplinary breast 
care, formally addressed by the European Parliament in 
2006 to support its general application in the European 
Union from 2016 [36] and recently adopted in Italy by the 
Conferenza Stato-Regioni1 [37]. On the other side, the con-
cept of cancer survivorship care (i.e., the survival status as 
a phase of a continued cancer care) [38] is progressively 
adopted by health systems. This phase starts at the end of 
primary treatment and should offer specialized comprehen-
sive answers to the person’s needs: information on life 
styles; management of comorbidities and of side effects of 
treatments; identification of long-term physical, psycholog-
ical, and social effects of the disease and disease-related 
treatments; identification of disease effects on families; 
evaluation of survival quality. The complexity of these 
issues makes the Breast Unit the most appropriate facility 
for offering a comprehensive follow-up service to these 
women.
However, we should not use the concept of cancer 
survivorship care to change the condition of women pre-
viously treated for BC into long-term survivors, taking 
into consideration also the economic impact of long-term 
intensive surveillance protocols. If we really evaluate the 
psychological impact of a BC diagnosis and of the sub-
sequent recovery, after a first phase of intensive relation-
ship of the patient with the facility where the treatment 
has been done, it appears to be important that we consider 
these women not as survivors but as an important subset of 
women at increased risk for BC. As a consequence, these 
1 In official Italian documents, the Breast Unit denomination has 
been translated into Centro di Senologia.
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women should be included into invitation lists of screen-
ing programs, with a frequency and modalities adapted 
to the increased risk level. This strategy is derived from a 
comprehensive evaluation, not only from considering eco-
nomic cost of prolonged intensive surveillance in the clini-
cal setting.
In this perspective, follow-up of women previously 
treated for BC should be active, i.e., using a centralized 
invitation system, and have a territorial basis as an insti-
tutional activity dedicated to all prevalent BC cases. This 
approach should also protect all women previously treated 
for BC, providing them with a planned access to mammog-
raphy also when, in the case of spontaneous surveillance, 
for different reasons such as other relevant familial events 
and psychological removal of the BC occurrence, the mam-
mogram would be deferred or not performed at all [31]. 
Moreover, in this way we could also offer a protection to 
those women who are treated for BC at major hospitals or 
cancer centers but live in different regions, as frequently 
occurs in Italy.
The general perspective is that screening and clinical 
breast imaging will be offered by the same Department 
of Radiology, in the context of a Breast Unit. The current 
implementation of the Breast Units in Italy and their con-
nection with screening programs have to be considered 
a transition process, which is relevant for the following 
recommendations.
Recommendations
The Breast Unit should define a dedicated follow-up proto-
col for women already treated for BC. This protocol should 
describe responsibilities, invitation, facilities, radiological 
and clinical procedures, and duration of the follow-up. Role 
and function of family doctors and BC specialists should be 
also defined.
Women already treated for any BC (screen-detected 
BCs from organized population-based programs, interval 
cancers, BC cases diagnosed outside screening programs 
in asymptomatic or symptomatic women) should not be 
excluded from screening invitation lists. Screening pro-
grams, in the context of the Breast Unit, should invite for 
a mammogram those women treated for BC who reside in 
the catchment area, independently of the age at diagnosis 
and current woman’s age, at least up to 74 years of age, 
starting from the year following treatment. These women 
should be examined in dedicated sessions (for cases of 
bilateral mastectomy, see below). The follow-up duration 
should not be shorter than 10 years and will be defined on 
the basis of woman’s age and local considerations.
If another service or center has included one of these 
woman in a follow-up program (e.g., the cancer center 
where the BC was treated) and informs the Breast Unit 
of this, the Breast Unit should be open to make an agree-
ment with the other service for excluding or including that 
woman in the invitation list. If the invited woman declares 
to prefer to be followed by another service, the Breast Unit 
should notify to this service the woman’s willingness and 
plan not to invite her for the time indicated by the other 
center.
The dedicated screening sessions should be organized 
according to a defined protocol, here summarized as an 
indicative reference:
1. investigation of personal/familial history (if not already 
done) to identify high-risk conditions for which a dif-
ferent screening strategy should be adopted;
2. CBE and possible breast ultrasound performed by a 
breast radiologist in the case of bilateral mastectomy;
3. immediate mammogram reading by a breast radiologist 
(single reading) or, when possible, by two breast radi-
ologists (blinded double reading);
4. immediate performance of supplemental investigations 
(CBE, other mammographic views, tomosynthesis and/
or breast ultrasound, and, whenever possible, needle 
sampling);
5. fast scheduling (preferably within ten working days) of 
further workup including, if indicated, MRI, according 
to guidelines [17, 18, 39].
The key point of the protocol should be the immediate 
communication of the results of the session to the woman, 
possibly with personal interaction between the breast radi-
ologist and the woman and with a written report.
In the case of single reading to reach a diagnostic con-
clusion to be immediately communicated to the woman, the 
second reading is waived considering that the comprehen-
sive clinical evaluation can also include the above-men-
tioned supplemental techniques. However, although psy-
chological issues would advise against a delayed second 
reading, this option can be considered if a high-quality 
interaction with the woman is undertaken.2
The Breast Unit should coordinate as much as possible 
the breast follow-up rounds and other follow-up visits, try-
ing to allow the woman to have all visits on the same day.
2 When the delayed second reading is applied, the breast radiologist 
who works as first reader, in the case of suspicious finding(s), will 
perform all suitable workup, while, in the case of negative evaluation, 
will give the woman the negative report in order to reassure her. How-
ever, at the same time, the radiologist will inform the woman that her 
mammograms will be read also in a delayed time by second reader 
(according the usual protocol for screening mammography) who 
occasionally could recall the woman for further workup. This infor-
mation will be also included in the negative written report.
895Radiol med (2016) 121:891–896 
1 3
Considering the special features of these dedicated ses-
sions, costs should be specifically evaluated. Payments 
should be differentiated from those of screening mam-
mography offered to the general female population in the 
absence of BC history.
Data about screening results of women already treated 
for BC should be hived off from those regarding the gen-
eral female population invited to screening and should 
be presented in dedicated annual reports, as happens in 
other countries [30]. In particular, among the other usual 
indicators, attention should be paid to: crude and adjusted 
response rate; prevalent BC cases; quantity and quality of 
the offered service; and women’s satisfaction evaluation. 
Results from both single reading protocols and blinded 
double reading protocols (either with immediate or delayed 
second reading) will undergo an evaluation by the Breast 
Unit, paying careful attention to: ipsilateral or contralateral 
relapse diagnosed at stage T2 or greater; interval cancer 
analysis; in the case of delayed second reading, additional 
recall rate due to the second reading and compliance rate in 
the following rounds.
From the viewpoint of the economic impact, apart from 
the already mentioned specific reimbursement negotiations, 
the authors evaluate that the cost cannot be superior to that 
implied by the current practice of annual CBE and mam-
mography with or without breast ultrasound, commonly 
performed in women with previous BC history. However, 
the implementation of such a protocol will require time 
and specific organizational choices, also considering the 
inhomogeneity of Breast Unit organization in the Italian 
regions.
Follow-up of women already treated for BC should be 
considered as a strategic area of BC research. In particular, 
we suggest the following research lines:
1. value of double reading (immediate or delayed) when 
screening women already treated for BC, with studies 
specifically designed (blinded sequential reading with 
or without arbitration, randomized controlled trials) 
and including both ipsilateral and contralateral cases;
2. usefulness of a further risk stratification and effective-
ness of different follow-up protocols, which may be 
tuned to pathologic and biomolecular features of the 
first BC and patient’s age and history and may be eval-
uated using surrogate endpoints;
3. value of different models for survivorship care [40], 
also in terms of cost-effectiveness.
Starting 3 years after the publication of these recommen-
dations, GISMa and ICBR/SIRM will evaluate the degree 
of their implementation in Italy through surveys among 
their members.
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